Related Experiment Video

Updated: Aug 30, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis

Robert N Chernish1, Shawn D Aaron

  • 1Division of Respiratory Medicine, University of Ottawa, Ontario, Canada.

Current Opinion in Pulmonary Medicine
|October 10, 2003
PubMed
Abstract

Insights

Antibiotic resistance in cystic fibrosis (CF) lung infections is rising. New lab tests help optimize antibiotic treatments for CF patients, with future therapies targeting biofilms and using antimicrobial peptides.

Area of Science:

  • Pulmonary Medicine
  • Infectious Diseases
  • Microbiology

Background:

  • Cystic fibrosis (CF) patients are living longer, leading to more chronic pulmonary bacterial infections.
  • Antibiotic treatment has driven the rise of antibiotic resistance in CF bacterial isolates.
  • Key pathogens include Pseudomonas aeruginosa and Burkholderia cepacia.

Purpose of the Study:

  • To review the challenge of antibiotic resistance in CF pulmonary infections.
  • To discuss current and future therapeutic strategies.
  • To highlight the role of laboratory testing in optimizing treatment.

Main Methods:

  • Review of bacterial resistance mechanisms (mutation, gene transfer).
  • Analysis of biofilm formation as a survival strategy.
  • Evaluation of in vitro synergy and multiple-combination bactericidal testing.

Main Results:

  • Bacteria like P. aeruginosa and B. cepacia develop resistance through mutation and gene transfer.
  • Biofilm formation enhances bacterial survival in CF airways.
  • In vitro testing guides selection of optimal antibiotic combinations for acute exacerbations.

Conclusions:

  • Laboratory-based synergy and multiple-combination bactericidal testing optimize antibiotic strategies for resistant CF infections.
  • Clinical trials are needed to confirm if susceptibility-guided treatment improves outcomes.
  • Future approaches may involve biofilm disruption and cationic antimicrobial peptides.

More Related Videos

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Microbiota of the Respiratory Tract01:29

Microbiota of the Respiratory Tract

The human respiratory tract, comprising the upper and lower segments, serves as a critical interface with the external environment. The upper respiratory tract (URT)—including the nostrils, sinuses, pharynx, and oropharynx—is heavily colonized by microbes, while the lower respiratory tract (LRT), composed of the larynx, trachea, bronchi, and lungs, was long thought to be sterile. However, recent molecular studies have revealed that the lungs are not devoid of microbes but act more like...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: